Themis CEO: Chikungunya Vaccine Could Be Approved In Two Years
Executive Summary
Themis Bioscience CEO says the biotech’s €40m Series D financing will fund pivotal trials for its lead vaccine candidate for chikungunya and advance its oncology franchise.